Background Anxiety and related disorders are among the most common mental disorders,
with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are …

These practice guidelines are intended to assist physicians in clinical decision making by
describing a range of generally acceptable approaches for the diagnosis and management …

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002,
World J Biol Psychiatry 3: 171), recommendations for the pharmacological treatment of …

Abstract The Sheehan Disability Scale (SDS) is a patient-rated, discretized analog measure
of functional disability in work, social, and family life. Its increasing use in clinical trials in …

scribí la primera edición de Fisiología de la Conducta hace más de un cuarto de siglo.
Cuando lo hice no podía imaginarme que algún día estaría escribiendo la octava edición …

Background: Biases in adverse effect reporting in randomized controlled trials (RCTs)[eg
due to investigator expectations or assessment quality] can be quantified by studying the …

Serotonin reuptake inhibitors and benzodiazepines are evidence-based pharmacological
treatments for Anxiety Disorders targeting serotonin and GABAergic systems, respectively …

Objectives: The primary objective of this study was to determine whether intracoronary
administration of the adenoviral gene for fibroblast growth factor (Ad5FGF-4) can improve …

Background: Escitalopram, the therapeutically active isomer of the racemic selective
serotonin reuptake inhibitor antidepressant citalopram, has shown significant anxiolytic …

This article reviews the evidence from randomized, placebo‐controlled trials and meta‐
analyses of pharmacological treatments of the following anxiety disorders: generalized …